Hartsfield syndrome

Hartsfield syndrome is an extremely rare genetic disorder characterized by the combination of holoprosencephaly (a failure of the forebrain to properly divide into two hemispheres during embryonic development) and ectrodactyly (split hand/foot malformation, also known as lobster-claw deformity). This condition affects multiple body systems, most prominently the central nervous system and the limbs. The syndrome was first described by Hartsfield in 1984 and has since been associated with mutations in the FGFR1 gene, which plays a critical role in embryonic development, particularly in brain formation and limb patterning. Clinical features vary in severity but typically include varying degrees of holoprosencephaly (ranging from alobar to lobar forms), ectrodactyly of the hands and/or feet, and craniofacial anomalies such as midface hypoplasia, hypertelorism or hypotelorism, cleft lip and/or palate, and microcephaly. Additional features may include intellectual disability, developmental delay, seizures, endocrine abnormalities (particularly diabetes insipidus and growth hormone deficiency related to hypothalamic-pituitary dysfunction), and eye anomalies. Some patients also exhibit nasal anomalies including absent or hypoplastic nasal structures. There is no cure for Hartsfield syndrome, and management is supportive and symptomatic. Treatment may include hormone replacement therapy for endocrine deficiencies, antiepileptic medications for seizures, surgical correction of limb and craniofacial anomalies where feasible, and developmental support services. Prognosis depends largely on the severity of the holoprosencephaly, with more severe forms associated with significant morbidity and early mortality. A multidisciplinary team approach involving neurology, endocrinology, orthopedics, genetics, and developmental specialists is essential for optimal care.

Common questions about Hartsfield syndrome